Understanding how a new adjuvant boosts immune responses in vaccines
Mechanisms of combined CD40/TLR adjuvant-elicited cellular immunity
This study is looking at how a special mix of immune boosters can help your body create stronger and longer-lasting defenses against infections by improving certain types of immune cells, and it's aimed at making vaccines even better for everyone.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11041121 on NIH RePORTER |
What this research studies
This research investigates how a specific combination of CD40 and TLR agonists can enhance the immune response by promoting long-lasting CD4+ and CD8+ T cell populations. The researchers aim to uncover the mechanisms behind this adjuvant's effectiveness compared to traditional methods. By analyzing the unique metabolic programs and cytokine requirements involved in T cell generation, they hope to improve vaccine design for better protection against pathogens. The study includes computational modeling to simulate T cell behavior in response to antigen challenges.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of infections that could be prevented by improved vaccine strategies.
Not a fit: Patients who are not at risk of infectious diseases or those who have already received effective vaccinations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide long-lasting immunity against various diseases.
How similar studies have performed: Previous studies have shown promising results with similar adjuvant approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Kedl, Ross M — University of Colorado Denver
- Study coordinator: Kedl, Ross M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.